A Phase III, randomized, open label, cross-over, multi-center, safety and efficacy study to evaluate nab-paclitaxel (Abraxane) as maintenance treatment after induction with nab-paclitaxel plus carboplatin in subjects with squamous cell non-small cell lung cancer (NSCLC) - Regional Cancer Care Associates LLC

Clinical Trials

A Phase III, randomized, open label, cross-over, multi-center, safety and efficacy study to evaluate nab-paclitaxel (Abraxane) as maintenance treatment after induction with nab-paclitaxel plus carboplatin in subjects with squamous cell non-small cell lung cancer (NSCLC)

Type of Cancer
Lung
Locations
Bethesda
Sponsor
Celgene
Protocol Number
ABI-007-NSCL-003
Cancer Diagnosis
To Learn More Call
201-510-0910